The story of Viagra, and its developer copyright, presents a challenging case study for investors. Initially a blockbuster drug, yielding billions in sales , its patent expiration created a deluge of knock-off medications, significantly eroding its dominance. While some pharmaceutical companies may seek to capitalize on male sexual dysfunction, the